bioMérieux – First-Half 2017 Results

30 August, 2017

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 29 under the chairmanship of Jean-Luc Belingard and approved the consolidated financial statements for the six months ended June 30, 2017. The statements had been reviewed by the Statutory Auditors.

  • Solid sales dynamic, with sales up 11.3% over the first half at constant exchange rates and scope of consolidation:
    • €1,134 million in sales
    • Up 13.3% as reported
  • 30-bp improvement in contributive operating margin before non-recurring items, which came out at 15.2% of sales
  • Sharp 18% increase in net income to €101 million
  • 2017 financial targets revised:
    • Organic growth in sales of between 9% and 10%
    • Contributive operating income before non-recurring items of between €330 million and €345 million

Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux has achieved very satisfactory sales and operating results for the first six months of the year. In light of this dynamic performance, as well as the more-favorable-than-expected currency environment, we are able to revise our full-year financial targets upward while pursuing our innovation and development efforts for the long term."

2017 Objectives

In light of the robust organic growth reported in the first half and based on the information available to bioMérieux, the Company is now targeting organic sales growth for the full year of between 9% and 10%.

Given the more-favorable-than-expected exchange rates in the first half and the revised target for full-year organic sales growth, bioMérieux is now aiming to deliver full-year contributive operating income before non-recurring items of between €330 million and €345 million. This new target takes into account the Group's ongoing efforts in sales and innovation as part of a long-term strategy and is subject to current exchange rates holding firm in the second half of the year.

Jean-Luc Belingard, Chairman, said: "bioMérieux had an excellent first half. Combining strong organic growth in sales and a significant increase in earnings, the Company's performance confirms the validity of our strategic focus on the fight against infectious diseases and also reflects our disciplined day-to-day operational management. This is what prompted our decision to raise our financial objectives for full-year 2017."

About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2016, revenues reached €2,103 million with 90% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market
Symbol: BIM – ISIN: FR0010096479
Reuters: BIOX.PA/Bloomberg: BIM.FP ).

Corporate website:
Investor website:


Investor Relations

Sylvain Morgeau
Tel.: +33 (0)4 78 87 22 37

Media Relations

Aurore Sergeant
Tel.: +33 (0)4 78 87 54 75

Image Sept
Laurence Heilbronn
Tel.: +33 (0)1 53 70 74 64

Claire Doligez
Tel.: +33 (0)1 53 70 74 48

Download the Full Press Release:

Pioneering Diagnostics